---
figid: PMC6839656__02mjms26052019_ra1f8
figlink: /pmc/articles/PMC6839656/figure/f8-02mjms26052019_ra1/
number: F8
caption: Effect of andrographolide and Simvastatin on the mevalonate pathway in HL-60
  leukaemia cells. Andrographolide inhibits the HMGCR activity and this affects the
  downstream pathway of cholesterol biosynthesis [image taken from Chen et al. ()]
pmcid: PMC6839656
papertitle: Andrographolide is an Alternative Treatment to Overcome Resistance in
  ER-Positive Breast Cancer via Cholesterol Biosynthesis Pathway.
reftext: Harishini Rajaratinam, et al. Malays J Med Sci. 2019 Sep;26(5):6-20.
pmc_ranked_result_index: '62610'
pathway_score: 0.955921
filename: 02mjms26052019_ra1f8.jpg
figtitle: Effect of andrographolide and Simvastatin on the mevalonate pathway in HL-60
  leukaemia cells
year: '2019'
organisms:
- Homo sapiens
ndex: 8a3f0d89-dee0-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6839656__02mjms26052019_ra1f8.html
  '@type': Dataset
  description: Effect of andrographolide and Simvastatin on the mevalonate pathway
    in HL-60 leukaemia cells. Andrographolide inhibits the HMGCR activity and this
    affects the downstream pathway of cholesterol biosynthesis [image taken from Chen
    et al. ()]
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - AKT2
  - AKT3
  - AKT1
  - MAPK1
  - MAPK3
  - RASA1
  - GCLC
  - SLC2A4RG
  - GLO1
  - MCL1
  - CFLAR
  - NFKB1
  - RAF1
  - NRAS
  - HRAS
  - KRAS
  - Simvastatin
  - Glucose
  - D-lactate
  - GDP
  - Methylglyoxal
  - Acetyl-CoA
  - LY294002
  - U0126
  - Mevalonate
  - GSH
  - Farnesyl
  - Cholesterol
  - Cancer
genes:
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: ERK1/2
  symbol: ERK2
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: ERK1/2
  symbol: ERK1
  source: hgnc_alias_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: GAP
  symbol: GAP
  source: hgnc_alias_symbol
  hgnc_symbol: RASA1
  entrez: '5921'
- word: GCLC
  symbol: GCLC
  source: hgnc_symbol
  hgnc_symbol: GCLC
  entrez: '2729'
- word: GEF
  symbol: GEF
  source: hgnc_alias_symbol
  hgnc_symbol: SLC2A4RG
  entrez: '56731'
- word: GLO1
  symbol: GLO1
  source: hgnc_symbol
  hgnc_symbol: GLO1
  entrez: '2739'
- word: Mcl-1,
  symbol: Mcl-1
  source: hgnc_alias_symbol
  hgnc_symbol: MCL1
  entrez: '4170'
- word: Mcl-1,BelxL,CFLIP
  symbol: c-FLIP
  source: hgnc_alias_symbol
  hgnc_symbol: CFLAR
  entrez: '8837'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: Raf-1
  symbol: Raf-1
  source: hgnc_alias_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: Ras-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: Ras-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: Ras-GTP
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals:
- word: Simvastatin
  source: MESH
  identifier: D019821
- word: Glucose
  source: MESH
  identifier: D005947
- word: D-lactate
  source: MESH
  identifier: D019344
- word: GDP
  source: MESH
  identifier: D006153
- word: Methylglyoxal
  source: MESH
  identifier: D011765
- word: Acetyl-CoA
  source: MESH
  identifier: D000105
- word: LY294002
  source: MESH
  identifier: C085911
- word: U0126
  source: MESH
  identifier: C113580
- word: Mevalonate
  source: MESH
  identifier: D008798
- word: GSH
  source: MESH
  identifier: D005978
- word: Farnesyl
  source: MESH
  identifier: C042455
- word: Cholesterol
  source: MESH
  identifier: D002784
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC6839656__F8
redirect_from: /figures/PMC6839656__F8
figtype: Figure
---
